BVXV
Price:
$1.36
Market Cap:
$4.97M
BiondVax Pharmaceuticals Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious diseases and other illnesses in Israel. The company has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was incorporated in 2003 and is headquartered in Jerusalem, Israel.[Read more]
Industry
Biotechnology
IPO Date
2015-05-12
Stock Exchange
NASDAQ
Ticker
BVXV
According to BiondVax Pharmaceuticals Ltd.’s latest financial reports and current stock price. The company's current PE Ratio is -0.58. This represents a change of -100.00% compared to the average of 24.92K of the last 4 quarters.
The mean historical PE Ratio of BiondVax Pharmaceuticals Ltd. over the last ten years is -420353.56. The current -0.58 PE Ratio has changed -99.99% with respect to the historical average. Over the past ten years (40 quarters), BVXV's PE Ratio was at its highest in in the December 2022 quarter at 99.70K. The PE Ratio was at its lowest in in the December 2016 quarter at -716.97.
Average
-420353.56
Median
-4.36
Minimum
-4203514.43
Maximum
14.68
Discovering the peaks and valleys of BiondVax Pharmaceuticals Ltd. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 207.43%
Maximum Annual PE Ratio = 14.68
Minimum Annual Increase = -796.06%
Minimum Annual PE Ratio = -4203514.43
Year | PE Ratio | Change |
---|---|---|
2022 | -4203514.43 | 207.43% |
2021 | -2.03 | -113.80% |
2020 | 14.68 | -796.06% |
2019 | -2.11 | -57.75% |
2018 | -4.99 | 79.36% |
2017 | -2.78 | -41.21% |
2016 | -4.73 | 18.61% |
2015 | -3.99 | -51.26% |
2014 | -8.19 | 16.31% |
2013 | -7.04 | 7.82% |
The current PE Ratio of BiondVax Pharmaceuticals Ltd. (BVXV) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-1401167.26
5-year avg
-840701.78
10-year avg
-420353.56
BiondVax Pharmaceuticals Ltd.’s PE Ratio is greater than First Wave BioPharma, Inc. (-0.85), less than Salarius Pharmaceuticals, Inc. (-0.13), greater than SAB Biotherapeutics, Inc. (-0.93), less than Vaccinex, Inc. (-0.33), less than GeoVax Labs, Inc. (-0.17), greater than Molecular Partners AG (-3.01), greater than Mineralys Therapeutics, Inc. (-5.57), less than AN2 Therapeutics, Inc. (-0.50), greater than Pharvaris N.V. (-10.46), greater than PepGen Inc. (-2.47), greater than Can-Fite BioPharma Ltd. (-531.40), greater than Oramed Pharmaceuticals Inc. (-21.89), greater than MediWound Ltd. (-8.52), greater than BioLineRx Ltd. (-1.13), greater than Surrozen, Inc. (-0.70), greater than Armata Pharmaceuticals, Inc. (-1.27), less than Pasithea Therapeutics Corp. (-0.23), less than Oncternal Therapeutics, Inc. (-0.12), less than Aditxt, Inc. (-0.02), less than Adial Pharmaceuticals, Inc. (-0.34), less than TransCode Therapeutics, Inc. (-0.20), greater than Reviva Pharmaceuticals Holdings, Inc. (-1.05), less than Avenue Therapeutics, Inc. (-0.24),
Company | PE Ratio | Market cap |
---|---|---|
-0.85 | $5.99M | |
-0.13 | $2.09M | |
-0.93 | $37.29M | |
-0.33 | $9.06M | |
-0.17 | $15.26M | |
-3.01 | $247.30M | |
-5.57 | $671.31M | |
-0.50 | $32.23M | |
-10.46 | $1.29B | |
-2.47 | $221.28M | |
-531.40 | $15.23M | |
-21.89 | $97.44M | |
-8.52 | $197.82M | |
-1.13 | $37.41M | |
-0.70 | $38.09M | |
-1.27 | $85.03M | |
-0.23 | $3.78M | |
-0.12 | $4.38M | |
-0.02 | $4.28M | |
-0.34 | $6.44M | |
-0.20 | $8.89M | |
-1.05 | $33.39M | |
-0.24 | $3.15M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like BiondVax Pharmaceuticals Ltd. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like BiondVax Pharmaceuticals Ltd. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is BiondVax Pharmaceuticals Ltd.'s PE Ratio?
How is the PE Ratio calculated for BiondVax Pharmaceuticals Ltd. (BVXV)?
What is the highest PE Ratio for BiondVax Pharmaceuticals Ltd. (BVXV)?
What is the 3-year average PE Ratio for BiondVax Pharmaceuticals Ltd. (BVXV)?
What is the 5-year average PE Ratio for BiondVax Pharmaceuticals Ltd. (BVXV)?
How does the current PE Ratio for BiondVax Pharmaceuticals Ltd. (BVXV) compare to its historical average?